Polycythemia vera · 7 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ruxolitinib monotherapy Variant #06 | — | R 24 260 | — | — | — | ~7 | ~R 169 820 PFS proxy · indirect | 2 |
Thalidomide monotherapy Variant #04 | — | R 8 341 | 28d | ~23.0 mo | — | ~2 | ~R 16 682 PFS proxy · indirect | 1 |
Anagrelide monotherapy Variant #01 | — | R 6 061 | 28d | — | — | ~2 | ~R 12 122 indirect | — |
Lenalidomide monotherapy Variant #01 | — | R 2 178 | 28d | ~39.0 mo | ~113.8 mo | ~24 | ~R 52 272 PFS proxy · indirect | 10 |
Hydroxyurea monotherapy Variant #01 | — | R 265 | 28d | — | ~243.6 mo | ~2 | ~R 529 PFS proxy · indirect | — |
Peginterferon alfa-2a monotherapy Variant #01 Partial | — | — | 7d | — | — | ~2 | — | — |
Pipobroman monotherapy Variant #01 Partial | — | — | — | — | ~184.8 mo | ~1 | — | — |
7 of 7 regimens shown